170 related articles for article (PubMed ID: 22721929)
1. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens.
Chen KH; Lin JL; Lin-Tan DT; Hsu HH; Hsu CW; Hsu KH; Yen TH
Am J Kidney Dis; 2012 Oct; 60(4):530-8. PubMed ID: 22721929
[TBL] [Abstract][Full Text] [Related]
2. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.
Lin JL; Lin-Tan DT; Hsu KH; Yu CC
N Engl J Med; 2003 Jan; 348(4):277-86. PubMed ID: 12540640
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases.
Lin-Tan DT; Lin JL; Yen TH; Chen KH; Huang YL
Nephrol Dial Transplant; 2007 Oct; 22(10):2924-31. PubMed ID: 17556414
[TBL] [Abstract][Full Text] [Related]
4. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes.
Lin JL; Lin-Tan DT; Yu CC; Li YJ; Huang YY; Li KL
Kidney Int; 2006 Jun; 69(11):2049-56. PubMed ID: 16641918
[TBL] [Abstract][Full Text] [Related]
5. Low-level environmental exposure to lead and progressive chronic kidney diseases.
Lin JL; Lin-Tan DT; Li YJ; Chen KH; Huang YL
Am J Med; 2006 Aug; 119(8):707.e1-9. PubMed ID: 16887418
[TBL] [Abstract][Full Text] [Related]
6. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial.
Lin JL; Ho HH; Yu CC
Ann Intern Med; 1999 Jan; 130(1):7-13. PubMed ID: 9890856
[TBL] [Abstract][Full Text] [Related]
7. Is lead chelation therapy effective for chronic kidney disease? A meta-analysis.
Yang SK; Xiao L; Song PA; Xu XX; Liu FY; Sun L
Nephrology (Carlton); 2014 Jan; 19(1):56-9. PubMed ID: 24341661
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
Bolton WK; Cattran DC; Williams ME; Adler SG; Appel GB; Cartwright K; Foiles PG; Freedman BI; Raskin P; Ratner RE; Spinowitz BS; Whittier FC; Wuerth JP;
Am J Nephrol; 2004; 24(1):32-40. PubMed ID: 14685005
[TBL] [Abstract][Full Text] [Related]
9. ["Terzo fuoco", lead poisoning and chronic renal failure].
Bonucchi D; Mondaini G; Ravera F; Minisci E; Albertazzi V; Arletti S; Mori G; Ballestri M; Piattoni J; Cappelli G
G Ital Nefrol; 2007; 24 Suppl 38():76-9. PubMed ID: 17922453
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
[TBL] [Abstract][Full Text] [Related]
11. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial.
Cortés-Sanabria L; Cabrera-Pivaral CE; Cueto-Manzano AM; Rojas-Campos E; Barragán G; Hernández-Anaya M; Martínez-Ramírez HR
Am J Kidney Dis; 2008 May; 51(5):777-88. PubMed ID: 18436088
[TBL] [Abstract][Full Text] [Related]
12. Environmental lead exposure and progressive renal insufficiency.
Lin JL; Tan DT; Hsu KH; Yu CC
Arch Intern Med; 2001 Jan; 161(2):264-71. PubMed ID: 11176742
[TBL] [Abstract][Full Text] [Related]
13. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
[TBL] [Abstract][Full Text] [Related]
14. Long-term renal function preservation after renal artery stenting in patients with progressive ischemic nephropathy.
Rocha-Singh KJ; Ahuja RK; Sung CH; Rutherford J
Catheter Cardiovasc Interv; 2002 Oct; 57(2):135-41. PubMed ID: 12357507
[TBL] [Abstract][Full Text] [Related]
15. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
16. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
[TBL] [Abstract][Full Text] [Related]
17. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
18. [Case of lead nephropathy due to chronic occupational lead exposure].
Ogata A; Sueta S; Tagawa M
Nihon Jinzo Gakkai Shi; 2011; 53(2):207-11. PubMed ID: 21516708
[TBL] [Abstract][Full Text] [Related]
19. Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients?
Fontseré N; Salinas I; Bonal J; Bayés B; Riba J; Torres F; Rios J; Sanmartí A; Romero R
Nephrol Dial Transplant; 2006 Aug; 21(8):2152-8. PubMed ID: 16702203
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
